{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:59:16Z","timestamp":1775804356430,"version":"3.50.1"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cardiovascular-kidney-metabolic (CKM) syndrome is a recently defined clinical entity that encompasses cardiovascular disease (CVD), chronic kidney disease (CKD) and metabolic disorders. It has emerged as a growing public health concern that adversely affects the quality of life and imposes a substantial burden on human health. Sodium-glucose cotransporter 2 inhibitor (SGLT-2i) is a novel class of oral hypoglycemic agent with novel insulin-independent mechanism. In the last decade, published studies highlight its substantial effects on renal and cardiovascular outcomes. SGLT-2i is recommended for patients with stages 2\u20134 CKM syndrome, particularly those with CKD or diabetes to delay disease progression, and improve long-term clinical outcomes. This review comprehensively summarizes the current clinical evidence and elucidates the underlying mechanisms of SGLT-2i in CKM syndrome. Glycosuria and natriuresis, the primary effects of SGLT2 inhibition, play a pivotal role in improving glycemic control, reducing body weight, and lowering blood pressure. These initial effects trigger a cascade of downstream mechanisms: hemodynamic optimization via interstitial fluid reduction, enhanced cardiac efficiency through ketogenesis, and attenuation of inflammation and oxidative stress. Additional systemic benefits include increased fatty acid utilization, reduced hyperuricemia and stimulated erythropoiesis, thereby generating a network of interrelated therapeutic benefits in CKM syndrome. The pleiotropic effects of SGLT-2i position it as a highly promising therapeutic strategy for CKM syndrome. A deeper understanding of underlying mechanisms will better inform the application of SGLT-2i for this newly defined condition and guide optimal treatment strategies.<\/jats:p>","DOI":"10.3389\/fphar.2026.1800868","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:04:03Z","timestamp":1775801043000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Current understanding of sodium-glucose transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome"],"prefix":"10.3389","volume":"17","author":[{"given":"Yan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Nephrology, Changzhou First People\u2019s Hospital","place":["Changzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Changzhou First People\u2019s Hospital","place":["Changzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Changzhou First People\u2019s Hospital","place":["Changzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sydney C. W.","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, The University of Hong Kong","place":["Hong Kong SAR, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi-Cheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Nephrology, Zhongda Hospital, Southeast University School of Medicine","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1001\/jama.2024.6892","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020","volume":"331","author":"Aggarwal","year":"2024","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s11739-025-03902-w","article-title":"The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 diabetes mellitus and metabolic-associated steatotic liver disease","volume":"20","author":"Amin","year":"2025","journal-title":"Intern Emerg. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"113677","DOI":"10.1016\/j.bcp.2019.113677","article-title":"Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats","volume":"170","author":"Arag\u00f3n-Herrera","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"117236","DOI":"10.1016\/j.atherosclerosis.2023.117236","article-title":"SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type","volume":"394","author":"Bechmann","year":"2024","journal-title":"Atherosclerosis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"101527","DOI":"10.1016\/j.redox.2020.101527","article-title":"Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: role of heme oxygenase-1","volume":"32","author":"Behnammanesh","year":"2020","journal-title":"Redox Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.123.065517","article-title":"Metabolic communication by SGLT2 inhibition","volume":"149","author":"Billing","year":"2024","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/ejhf.1663","article-title":"Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial","volume":"22","author":"B\u00f6hm","year":"2020","journal-title":"Eur. J. Heart Fail"},{"key":"B12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12933-019-0839-8","article-title":"How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial","volume":"18","author":"Bosch","year":"2019","journal-title":"Cardiovasc Diabetol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","article-title":"Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial","volume":"145","author":"Butler","year":"2022","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","article-title":"Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction: a post hoc analysis of the EMPEROR-preserved trial","volume":"8","author":"Butler","year":"2023","journal-title":"JAMA Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","article-title":"Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure","volume":"2","author":"Byrne","year":"2017","journal-title":"JACC Basic Transl. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e006277","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (Nucleotide-Binding domain-like receptor protein 3) inflammasome activation in heart failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ. Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"104781","DOI":"10.1016\/j.phrs.2020.104781","article-title":"Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium","volume":"157","author":"Cappetta","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"C1573","DOI":"10.1152\/ajpcell.00351.2023","article-title":"Renal upregulation of NCC counteracts empagliflozin-mediated NHE3 inhibition in normotensive but not in hypertensive male rat","volume":"326","author":"Castro","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"100666","DOI":"10.1016\/j.lanepe.2023.100666","article-title":"The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes","volume":"31","author":"Ceriello","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"B22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","article-title":"Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach","volume":"151","author":"Chew","year":"2025","journal-title":"Circulation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bph.14859","article-title":"Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice","volume":"177","author":"Chiang","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e003666","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"B25","doi-asserted-by":"publisher","first-page":"155612","DOI":"10.1016\/j.metabol.2023.155612","article-title":"Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis","volume":"145","author":"Chun","year":"2023","journal-title":"Metabolism"},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacbts.2018.11.010","article-title":"Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction","volume":"4","author":"Connelly","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"Eur. Heart J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/metabo10040163","article-title":"A review of lipidomics of cardiovascular disease highlights the importance of isolating lipoproteins","volume":"10","author":"Ding","year":"2020","journal-title":"Metabolites"},{"key":"B30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"Herrington","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"175521","DOI":"10.1016\/j.ejphar.2023.175521","article-title":"Inhibition of SGLT2 co-transporter by dapagliflozin ameliorates tubular proteinuria and tubule-interstitial injury at the early stage of diabetic kidney disease","volume":"942","author":"Farias","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"104215","DOI":"10.1016\/j.ebiom.2022.104215","article-title":"Cardiorenal protection of SGLT2 inhibitors-perspectives from metabolic reprogramming","volume":"83","author":"Gao","year":"2022","journal-title":"EBioMedicine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"dgaa057","DOI":"10.1210\/clinem\/dgaa057","article-title":"Dapagliflozin suppresses hepcidin and increases erythropoiesis","volume":"105","author":"Ghanim","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","article-title":"Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2","volume":"61","author":"Ghezzi","year":"2018","journal-title":"Diabetologia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e176708","DOI":"10.1172\/JCI176708","article-title":"SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts","volume":"134","author":"Goedeke","year":"2024","journal-title":"J. Clin. Invest."},{"key":"B36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12933-020-01166-6","article-title":"Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort","volume":"19","author":"Guembe","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12933-016-0491-5","article-title":"Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin","volume":"16","author":"Hayashi","year":"2017","journal-title":"Cardiovasc Diabetol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Heerspink","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association Joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/2042018815575273","article-title":"Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes","volume":"6","author":"Hinnen","year":"2015","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"B45","doi-asserted-by":"publisher","first-page":"101690","DOI":"10.1016\/j.xcrm.2024.101690","article-title":"The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy","volume":"5","author":"Hu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jacbts.2019.07.010","article-title":"Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes","volume":"4","author":"Iborra-Egea","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0179960","DOI":"10.1371\/journal.pone.0179960","article-title":"Effects of canagliflozin on weight loss in high-fat diet-induced obese mice","volume":"12","author":"Ji","year":"2017","journal-title":"PLoS One"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/ejhf.1594","article-title":"Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis","volume":"21","author":"Jones","year":"2019","journal-title":"Eur. J. Heart Fail"},{"key":"B49","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jash.2017.07.005","article-title":"The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus","volume":"11","author":"Jordan","year":"2017","journal-title":"J. Am. Soc. Hypertens."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1111\/dom.14829","article-title":"Interconnection between cardiovascular, renal and metabolic disorders: a narrative review with a focus on Japan","volume":"24","author":"Kadowaki","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"B52","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cjca.2019.08.033","article-title":"Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results","volume":"36","author":"Kang","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.117.029166","article-title":"Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease","volume":"136","author":"Kappel","year":"2017","journal-title":"Circulation"},{"key":"B54","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"B55","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00392-022-02119-7","article-title":"The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial","volume":"112","author":"Kolwelter","year":"2023","journal-title":"Clin. Res. Cardiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"F692","DOI":"10.1152\/ajprenal.00053.2022","article-title":"SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in dahl SS rats","volume":"322","author":"Kravtsova","year":"2022","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc Diabetol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"589273","DOI":"10.3389\/fphar.2021.589273","article-title":"Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1038\/s41401-022-00885-8","article-title":"Direct cardio-protection of dapagliflozin against obesity-related cardiomyopathy via NHE1\/MAPK signaling","volume":"43","author":"Lin","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.cmet.2024.10.009","article-title":"SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation","volume":"36","author":"Liu","year":"2024","journal-title":"Cell Metab."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e040382","DOI":"10.1161\/JAHA.124.040382","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on stage 4 cardiovascular-kidney-metabolic syndrome: a propensity score-matched study","volume":"14","author":"Liu","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"B62","doi-asserted-by":"publisher","first-page":"944886","DOI":"10.3389\/fphar.2022.944886","article-title":"Empagliflozin activates Sestrin2-mediated AMPK\/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s42000-024-00621-3","article-title":"Limited preventive effects of empagliflozin against metabolic dysfunction-associated steatotic liver disease in a mouse model of fast food diet","volume":"24","author":"Makri","year":"2025","journal-title":"Horm. (Athens)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12916-023-02781-2","article-title":"SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes","volume":"21","author":"Marfella","year":"2023","journal-title":"BMC Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12933-023-02118-6","article-title":"GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes","volume":"23","author":"Marfella","year":"2024","journal-title":"Cardiovasc Diabetol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"B67","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1681\/ASN.0000000000000271","article-title":"Effects of empagliflozin on fluid overload, weight, and blood pressure in CKD","volume":"35","author":"Mayne","year":"2024","journal-title":"J. Am. Soc. Nephrol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/20009666.2018.1527667","article-title":"Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use","volume":"8","author":"Melnick","year":"2018","journal-title":"J. Community Hosp. Intern Med. Perspect."},{"key":"B71","doi-asserted-by":"publisher","first-page":"F824","DOI":"10.1152\/ajprenal.00314.2017","article-title":"Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model","volume":"315","author":"Mishima","year":"2018","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"Esc. Heart Fail"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American heart association","volume":"148","author":"Ndumele","year":"","journal-title":"Circulation"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American heart association","volume":"148","author":"Ndumele","year":"","journal-title":"Circulation"},{"key":"B75","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","article-title":"SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1","volume":"316","author":"Novikov","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1055\/s-0034-1395609","article-title":"Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-Receptor axis","volume":"47","author":"Ojima","year":"2015","journal-title":"Horm. Metab. Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.metabol.2019.06.006","article-title":"Effects of dapagliflozin and\/or insulin glargine on beta cell mass and hepatic steatosis in db\/db mice","volume":"98","author":"Omori","year":"2019","journal-title":"Metabolism"},{"key":"B79","doi-asserted-by":"publisher","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na\/H exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e123130","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"B81","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00395-023-01022-0","article-title":"Acute antiarrhythmic effects of SGLT2 inhibitors-dapagliflozin lowers the excitability of atrial cardiomyocytes","volume":"119","author":"Paasche","year":"2024","journal-title":"Basic Res. Cardiol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cardfail.2020.08.015","article-title":"Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors","volume":"26","author":"Packer","year":"2020","journal-title":"J. Card. Fail"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial","volume":"77","author":"Packer","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12933-020-00997-7","article-title":"Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat","volume":"19","author":"Park","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose Cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2042098621989134","DOI":"10.1177\/2042098621989134","article-title":"Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews","volume":"12","author":"Pelletier","year":"2021","journal-title":"Ther. Adv. Drug Saf."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","article-title":"Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Pollock","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"154799","DOI":"10.1016\/j.metabol.2021.154799","article-title":"Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists","volume":"120","author":"Prattichizzo","year":"2021","journal-title":"Metabolism"},{"key":"B92","doi-asserted-by":"publisher","first-page":"738848","DOI":"10.3389\/fendo.2021.738848","article-title":"Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system","volume":"12","author":"Puglisi","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1479164120953625","DOI":"10.1177\/1479164120953625","article-title":"Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials","volume":"17","author":"Rong","year":"2020","journal-title":"Diab Vasc. Dis. Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J. Transl. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"e13649","DOI":"10.1111\/obr.13649","article-title":"Association of metabolic syndrome and chronic kidney disease","volume":"25","author":"Scurt","year":"2024","journal-title":"Obes. Rev."},{"key":"B99","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"155657","DOI":"10.1016\/j.metabol.2023.155657","article-title":"SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis","volume":"146","author":"Shen","year":"2023","journal-title":"Metabolism"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e074068","DOI":"10.1136\/bmj-2022-074068","article-title":"Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"381","author":"Shi","year":"2023","journal-title":"BMJ"},{"key":"B102","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1681\/ASN.0000000000000491","article-title":"Effects of sodium-glucose Cotransporter-2 inhibitors on kidney outcomes across baseline cardiovascular-kidney-metabolic conditions: a systematic review and meta-analyses","volume":"36","author":"Siddiqi","year":"2025","journal-title":"J. Am. Soc. Nephrol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.2337\/db19-0991","article-title":"Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating Sestrin2-Mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced Obese mice","volume":"69","author":"Sun","year":"2020","journal-title":"Diabetes"},{"key":"B106","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"F761","DOI":"10.1152\/ajprenal.00552.2020","article-title":"Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats","volume":"320","author":"Thomson","year":"2021","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","article-title":"SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition","volume":"32","author":"Tomita","year":"2020","journal-title":"Cell Metab."},{"key":"B109","doi-asserted-by":"publisher","first-page":"10606","DOI":"10.3390\/ijms221910606","article-title":"Complex positive effects of SGLT-2 inhibitor empagliflozin in the liver, kidney and adipose tissue of hereditary hypertriglyceridemic rats: possible contribution of attenuation of cell senescence and oxidative stress","volume":"22","author":"Trnovska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B110","doi-asserted-by":"publisher","first-page":"165729","DOI":"10.1016\/j.bbadis.2020.165729","article-title":"CaMKII and GLUT1 in heart failure and the role of gliflozins","volume":"1866","author":"Trum","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B111","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"B112","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"B113","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/dom.13991","article-title":"Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: a subanalysis of EMPA-REG OUTCOME","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B117","doi-asserted-by":"publisher","first-page":"117414","DOI":"10.1016\/j.lfs.2020.117414","article-title":"Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPAR\u03b1 in vivo and in vitro","volume":"247","author":"Wei","year":"2020","journal-title":"Life Sci."},{"key":"B118","doi-asserted-by":"publisher","first-page":"826604","DOI":"10.3389\/fendo.2022.826604","article-title":"Effects of SGLT-2 inhibitors on vascular endothelial function and arterial stiffness in subjects with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B119","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"e13336","DOI":"10.1111\/obr.13336","article-title":"Sodium-glucose co-transporter 2 inhibitors on weight change and cardiometabolic profiles in individuals with overweight or obesity and without diabetes: a meta-analysis","volume":"22","author":"Wong","year":"2021","journal-title":"Obes. Rev."},{"key":"B122","doi-asserted-by":"publisher","first-page":"103183","DOI":"10.1016\/j.redox.2024.103183","article-title":"Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming","volume":"73","author":"Wu","year":"2024","journal-title":"Redox Biol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced Obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"B124","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.3892\/mmr.2018.9393","article-title":"Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1-receptor for advanced glycation end products-nuclear factor-\u03baB signaling pathway","volume":"18","author":"Yao","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"B125","doi-asserted-by":"publisher","first-page":"20406223221083509","DOI":"10.1177\/20406223221083509","article-title":"Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials","volume":"13","author":"Yip","year":"2022","journal-title":"Ther. Adv. Chronic Dis."},{"key":"B126","doi-asserted-by":"publisher","first-page":"152441","DOI":"10.1016\/j.semarthrit.2024.152441","article-title":"Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: a comparative effectiveness analysis","volume":"66","author":"Yokose","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"B127","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/hr.2017.14","article-title":"Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats","volume":"40","author":"Yoshikawa","year":"2017","journal-title":"Hypertens. Res."},{"key":"B128","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1800868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:04:04Z","timestamp":1775801044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1800868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":129,"alternative-id":["10.3389\/fphar.2026.1800868"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1800868","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1800868"}}